• Danaher (NYSE:DHR) has launched a multi billion euro debt offering.
• The company plans to use the proceeds primarily to finance its acquisition of Masimo Corporation.
• The transaction is expected to affect Danaher's capital structure and business mix once completed.

Danaher operates across life sciences and diagnostics, so adding Masimo's patient monitoring and medical technology portfolio would further extend its healthcare reach. For investors, the size and currency of the euro debt raise highlight how Danaher is funding growth outside its existing cash resources and credit facilities. The deal takes place amid continued interest in medical technology assets from large healthcare groups.

For you as a shareholder or potential investor, the focus now is on how the acquisition terms, integration plans, and added leverage fit with your risk tolerance and time horizon. Upcoming disclosures on Masimo, the debt structure, and any expected cost or revenue effects will be important inputs when assessing Danaher's evolving profile.

Stay updated on the most important news stories for Danaher by adding it to your watchlist or portfolio. Alternatively, explore our Community to discover new perspectives on Danaher.

Investor Checklist

Quick Assessment

• ✅ Price vs Analyst Target: At US$174.63 versus a consensus target of about US$250, the stock trades roughly 30% below where analysts see value.
• ✅ Simply Wall St Valuation: Shares are flagged as trading around 19% below the Simply Wall St estimate of fair value.
• ❌ Recent Momentum: The 30 day return of about 8.6% decline shows recent pressure on the share price.

There is only one way to know the right time to buy, sell or hold Danaher. Head to Simply Wall St's company report for the latest analysis of Danaher's fair value.

Key Considerations

• 📊 The multi billion euro debt raise shifts part of the Masimo acquisition funding onto the balance sheet. This means you are trading off extra leverage for a larger healthcare footprint.
• 📊 Watch the final debt terms, any changes to credit ratings, and future updates on Masimo integration and expected cost or revenue effects.
• ⚠️ Even with no flagged company specific risks in the data, higher debt means more sensitivity to interest costs and future refinancing conditions.

Dig Deeper

For the full picture including more risks and rewards, check out the complete Danaher analysis. Alternatively, you can visit the community page for Danaher to see how other investors believe this latest news will impact the company's narrative.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.